KalVista Pharmaceuticals (NASDAQ:KALV) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

KalVista Pharmaceuticals (NASDAQ:KALV) posted its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.04, Yahoo Finance reports.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV opened at $12.34 on Friday. The company has a market capitalization of $520.60 million, a PE ratio of -3.63 and a beta of 0.91. The company’s fifty day moving average is $13.17 and its 200-day moving average is $12.42. KalVista Pharmaceuticals has a 52 week low of $7.21 and a 52 week high of $16.88.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald raised KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 26th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $32.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday.

Insider Buying and Selling

In related news, CEO Benjamin L. Palleiko sold 14,215 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $12.01, for a total transaction of $170,722.15. Following the transaction, the chief executive officer now owns 242,527 shares in the company, valued at approximately $2,912,749.27. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO Benjamin L. Palleiko sold 14,215 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $12.01, for a total value of $170,722.15. Following the completion of the sale, the chief executive officer now owns 242,527 shares in the company, valued at $2,912,749.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Paul K. Audhya sold 2,135 shares of KalVista Pharmaceuticals stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $12.40, for a total transaction of $26,474.00. Following the transaction, the insider now directly owns 83,745 shares in the company, valued at $1,038,438. The disclosure for this sale can be found here. Insiders sold 23,452 shares of company stock worth $282,491 in the last quarter. 12.30% of the stock is owned by corporate insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.